Advertisement

Topics

ASCO highlights: KEYNOTE100

10:29 EDT 12 Jul 2018 | ecancermedicalscience

Prof Ledermann speaks with ecancer at BCGS 2018 about results from ASCO 2018, highlighting trials of pembrolizumab in relapsed ovarian cancer. He considers the results from these trials, and how the mixed results of KEYNOTE 100 could be lead to the...

Original Article: ASCO highlights: KEYNOTE100

NEXT ARTICLE

More From BioPortfolio on "ASCO highlights: KEYNOTE100"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...